Lei et al. showed that the ORR of crizotinib was similar between patients with and without brain metastases at baseline in Chinese patients with ALK-positive NSCLC (68.4% vs. 69.5%, P = 0.904) [19]. Here, ALK is linked to non-small cell lung carcinoma.